

Edgar Filing: JOHNSON & JOHNSON - Form DFAN14A

JOHNSON & JOHNSON
Form DFAN14A
November 13, 2002

SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE
SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.)

Filed by the Registrant []

Filed by a Party other than the Registrant [X]

Check the appropriate box:

[] Preliminary Proxy Statement

[] Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e) (2))

[] Definitive Proxy Statement

[] Definitive Additional Materials

[X] Soliciting Material Pursuant to 17C.F.R. 240.14a-12

ORAPHARMA, INC.

(Name of Registrant as Specified in its Charter)

Johnson & Johnson

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[] Fee computed on the table below per Exchange Act Rules 14a-6(i) (1)
and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

[] Fee paid previously with preliminary materials.

[] Check box if any part of the fee is offset as provided by Exchange Act

Edgar Filing: JOHNSON & JOHNSON - Form DFAN14A

the Johnson & Johnson family of companies.

Under the terms of the transaction, OraPharma shareholders will receive \$7.41 for each outstanding OraPharma share. The transaction is valued at approximately \$85 million, net of cash, and is expected to close in the first quarter of 2003 subject to customary closing conditions and regulatory approvals. The acquisition is not expected to have a material impact on revenues or earnings of Johnson & Johnson.

-more-

-2-

OraPharma's initial product, Arestin(TM), represents a therapeutic advance for the adjunct treatment of periodontal disease. Arestin(TM) is the first locally administered, time-released antibiotic encapsulated in microspheres that effectively controls the germs that can cause periodontal disease, a disease that affects more than 50 million people in the United States.

"The acquisition of OraPharma allows us to make an important entry into the professional marketplace," said Michael Sneed, President, Personal Products Company. "The addition of OraPharma broadens our portfolio of innovative oral health products."

Headquartered in Warminster, Pennsylvania, OraPharma's strategic focus is based in large part on their patented microsphere delivery technology with well characterized compounds. The company's other technological initiatives include a compound for the treatment of oral mucositis, an agent for bone and tissue regeneration, and a next generation periodontal therapeutic.

"Becoming part of the Johnson & Johnson family of consumer companies provides us with the resources to fully realize the potential of Arestin(TM)," said Michael D. Kishbauch, President and Chief Executive Officer of OraPharma. "In addition, our future pipeline of technologies offers the potential of additional novel therapeutics."

Personal Products Company, a division of McNeil-PPC, Inc., develops, produces and markets innovative Oral Health, Women's Health and Sanitary Protection products. It is a leader in the fast growing oral health market with a full line of floss, rinse and toothbrush products. Personal Products is also a leader in women's health products with vaginal yeast cures, personal lubricants, and urinary pain relief tablets. The company's comprehensive product line of sanitary protection products includes pantliners, tampons and maxi pads. Leading brands include Monistat(TM), KY-Brand Liquid(TM), REACH(TM), and Stayfree(TM), Carefree(TM), and o.b.(TM)

-more-

-3-

Johnson & Johnson, with approximately 107,000 employees, is the world's

Edgar Filing: JOHNSON & JOHNSON - Form DFAN14A

most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical and medical devices and diagnostics markets. Johnson & Johnson has 197 operating companies in 54 countries around the world, selling products in more than 175 countries.

(In connection with the above-described transactions, OraPharma, Inc. intends to file a proxy statement and other materials with the Securities and Exchange Commission. Security holders are urged to read the proxy statement and these other materials when they become available because they will contain important information. Security holders may obtain a free copy of the proxy statement and these other materials when they become available, as well as other materials filed with the Securities and Exchange Commission concerning OraPharma, Inc., at the Securities and Exchange Commission web site at <http://www.sec.gov>. Security holders of OraPharma, Inc. may also obtain for free the proxy statement and other documents filed by OraPharma, Inc. with the Securities and Exchange Commission in connection with the above-described transactions by directing a request to OraPharma, Inc. at 732 Louis Drive, Warminster, PA 18974; Attention: Investor Relations.

OraPharma, Inc. and its directors and executive officers may be deemed to be participants in the solicitation of proxies from OraPharma, Inc. stockholders with respect to the merger. Information regarding these directors and executive officers and their ownership of OraPharma, Inc. common stock is contained in the proxy statement for OraPharma, Inc.'s 2002 annual meeting of stockholders. Additional information regarding these directors and executive officers and their interests will be included in the proxy statement.)

#